Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism
Status:
Terminated
Trial end date:
2020-05-20
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover
study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100)
lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).